These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 1873781)

  • 1. Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4-hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres.
    O'Briant KC; Shpall EJ; Houston LL; Peters WP; Bast RC
    Cancer; 1991 Sep; 68(6):1272-8. PubMed ID: 1873781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of malignant clonogenic breast cancer cells from human bone marrow.
    Anderson IC; Shpall EJ; Leslie DS; Nustad K; Ugelstad J; Peters WP; Bast RC
    Cancer Res; 1989 Aug; 49(16):4659-64. PubMed ID: 2663144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin.
    Montgomery RB; Kurtzberg J; Rhinehardt-Clark A; Haleen A; Ramakrishnan S; Olsen GA; Peters WP; Smith CA; Haynes BF; Houston LL
    Bone Marrow Transplant; 1990 Jun; 5(6):395-402. PubMed ID: 2369680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement.
    De Fabritiis P; Bregni M; Lipton J; Greenberger J; Nadler L; Rothstein L; Korbling M; Ritz J; Bast RC
    Blood; 1985 May; 65(5):1064-70. PubMed ID: 3995166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation.
    Shpall EJ; Bast RC; Joines WT; Jones RB; Anderson I; Johnston C; Eggleston S; Tepperberg M; Edwards S; Peters WP
    Bone Marrow Transplant; 1991 Feb; 7(2):145-51. PubMed ID: 2049558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement.
    Bast RC; De Fabritiis P; Lipton J; Gelber R; Maver C; Nadler L; Sallan S; Ritz J
    Cancer Res; 1985 Feb; 45(2):499-503. PubMed ID: 3967224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies.
    Gulati SC; Shimazaki C; Lemoli RM; Atzpodien J; Clarkson BD
    Eur J Haematol Suppl; 1989; 51():164-72. PubMed ID: 2627987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination.
    Lemoli RM; Gasparetto C; Scheinberg DA; Moore MA; Clarkson BD; Gulati SC
    Blood; 1991 Apr; 77(8):1829-36. PubMed ID: 2015406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined chemoseparation and immunoseparation of clonogenic T lymphoma cells from human bone marrow using 2'-deoxycoformycin, deoxyadenosine, 3A1 monoclonal antibody, and complement.
    Haleem A; Kurtzberg J; Olsen GA; Rhinehardt-Clark A; Leslie DS; Ray L; Smith CA; Peters WP; Haynes BF; Bast RC
    Cancer Res; 1987 Sep; 47(17):4608-12. PubMed ID: 3113721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation.
    Shpall EJ; Anderson IC; Bast RC; Joines WT; Jones RB; Ross M; Edwards S; Eggleston S; Johnston C; Tepperberg M
    Prog Clin Biol Res; 1990; 333():321-35; discussion 336. PubMed ID: 2308989
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells.
    Roy DC; Griffin JD; Belvin M; Blättler WA; Lambert JM; Ritz J
    Blood; 1991 Jun; 77(11):2404-12. PubMed ID: 2039821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined ex vivo treatment with immunotoxins and mafosfamid: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts.
    Uckun FM; Stong RC; Youle RJ; Vallera DA
    J Immunol; 1985 May; 134(5):3504-15. PubMed ID: 3884712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates.
    Bregni M; De Fabritiis P; Raso V; Greenberger J; Lipton J; Nadler L; Rothstein L; Ritz J; Bast RC
    Cancer Res; 1986 Mar; 46(3):1208-13. PubMed ID: 3510720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic activity of an anti-transferrin receptor immunotoxin on normal and leukemic human hematopoietic progenitors.
    Cazzola M; Bergamaschi G; Dezza L; D'Uva R; Ponchio L; Rosti V; Ascari E
    Cancer Res; 1991 Jan; 51(2):536-41. PubMed ID: 1985771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological and pharmacological removal of small cell lung cancer cells from bone marrow autografts.
    Humblet Y; Feyens AM; Sekhavat M; Agaliotis D; Canon JL; Symann ML
    Cancer Res; 1989 Sep; 49(18):5058-61. PubMed ID: 2548708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the individual and combined reactivities of monoclonal antibodies H25, H366, and MY9 with normal progenitor cells and blast cells from patients with acute myeloblastic leukemia.
    Wisniewski D; Strife A; Arlin Z; Knowles R; Lambek C; Gulati S; McHendry B; McKenzie S; Clarkson B
    Leukemia; 1989 Jun; 3(6):446-52. PubMed ID: 2657231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elimination of B-lymphoma cells from human bone marrow: model experiments using monodisperse magnetic particles coated with primary monoclonal antibodies.
    Kvalheim G; Fodstad O; Pihl A; Nustad K; Pharo A; Ugelstad J; Funderud S
    Cancer Res; 1987 Feb; 47(3):846-51. PubMed ID: 3492268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purging of myeloma cells from bone marrow using monoclonal antibodies and magnetic immunobeads in combination with 4-hydroperoxycyclophosphamide.
    Shimazaki C; Inaba T; Murakami S; Fujita N; Nakagawa M; Gulati SC; Fried J; Clarkson BD; Wisniewolski R; Wang CY
    Prog Clin Biol Res; 1990; 333():311-9. PubMed ID: 2308988
    [No Abstract]   [Full Text] [Related]  

  • 19. Elimination of myeloma cells from bone marrow by using monoclonal antibodies and magnetic immunobeads.
    Shimazaki C; Wisniewski D; Scheinberg DA; Atzpodien J; Strife A; Gulati S; Fried J; Wisniewolski R; Wang CY; Clarkson BD
    Blood; 1988 Oct; 72(4):1248-54. PubMed ID: 3167207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial.
    Shpall EJ; Jones RB; Bast RC; Rosner GL; Vandermark R; Ross M; Affronti ML; Johnston C; Eggleston S; Tepperburg M
    J Clin Oncol; 1991 Jan; 9(1):85-93. PubMed ID: 1985173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.